Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2446 • ACR Convergence 2023
Intermittent Fasting Attenuates Cognitive Dysfunction in Murine Systemic Lupus Erythematosus
Yi Feng, Jiayu Qin, Lijuan Zheng, Hao Ren, Min Yang and Qin Huang, Department of Rheumatology, Nanfang Hospital, Southern Medical University, Guangzhou, China
Background/Purpose: Cognitive dysfunction is one of the most common manifestations of neuropsychiatric systemic lupus erythematosus (NPSLE) and severely affects patients' health-related quality of life. Intermittent…
Abstract Number: 2501 • ACR Convergence 2023
Selection of Indicators Reporting Response Rate in Pharmaceutical Trials for Systemic Lupus Erythematosus: Preference and Relative Sensitivity
Jingru Tian¹, Shuntong Kang², Dingyao Zhang³ and Qianjin Lu⁴, ¹Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China, ²Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital, Central South University, Nanjing, China, ³Graduate Program in Biological and Biomedical Sciences, Yale University, New Haven, CT, ⁴Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Changsha, China
Background/Purpose: Systemic lupus erythematosus (SLE) is a common multisystem autoimmune disease with chronic inflammation. Many efficacy evaluation indicators of randomized clinical trials (RCTs) for SLE…
Abstract Number: 2591 • ACR Convergence 2023
Under Assault: Ongoing Brain Dysfunction Identified on Resting State-functional MRI (rs-fMRI) in SLE Patients in Clinical Remission
Meggan MacKay, an vo, Erik Anderson, Cynthia Aranow, Betty Diamond and David Eidelberg, Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: There is substantial evidence that the brain is targeted early in SLE, likely from disease inception. Data from mouse models and human studies suggest…
Abstract Number: 0055 • ACR Convergence 2023
Elevated LINE-1 Expression in SLE Keratinocytes Leads to LINE-1 Reverse Transcriptase-dependent Type I Interferon Responses
Wenyan Miao¹, Daniel Rios¹, Mehrnaz Gharaee-Kermani², Craig Dobry², Artur Jaroszewicz¹, Cedric Arisdakessian¹, Enrique Garcia-Rivera¹, Nafeeza Hafeez¹, Brian Desrosiers¹, Jess Floro¹, Jared Steranka¹, Menachem Fromer¹, Dennis Zaller¹ and J. Michelle Kahlenberg², ¹Rome Therapeutics, Boston, MA, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Long Interspersed Element-1 (LINE-1) are retrotransposable DNA elements that make up ~17% of the human genome, and their role in health and disease is…
Abstract Number: 0156 • ACR Convergence 2023
Factors Associated with Adherence to Cervical Cancer Screening in Ethnically Diverse Women with Systemic Lupus Erythematosus
Sebastian Bruera¹, Savannah Bowman¹, Yinan Huang², Maria Suarez-Almazor³, Grace Lo¹, Elizabeth Chiao⁴, Maria A. Lopez-Olivo⁴ and Sandeep Agarwal¹, ¹Baylor College of Medicine, Houston, TX, ²Department of Pharmacy Administration, University of Mississippi School of Pharmacy, Oxford, MS, ³MD Anderson Cancer Center, Houston, TX, ⁴The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Women living with systemic lupus erythematosus (SLE) are at an increased risk of infections from human papillomavirus (HPV), and cervical cancer, especially women with…
Abstract Number: 0195 • ACR Convergence 2023
Assessing Cardiovascular Risk in Black and Latino Patients with Systemic Lupus Erythematosus
Glorielly Gonzalez¹, Zerai Manna², Alice Fike³, Jun Chu², sarfaraz Hasni² and Brian Dizon¹, ¹National Institute of Arthritis and Musculoskelatal and Skin Diseases, Bethesda, MD, ²Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Cardiovascular disease (CVD) is a major cause of mortality among patients with systemic autoimmune disease. Patients with systemic lupus erythematosus (SLE) exhibit accelerated cardiovascular…
Abstract Number: 0548 • ACR Convergence 2023
Clinical and Interferon Biomarkers to Exclude Imminent Autoimmune Disease in ANA Positive Individuals
Md Yuzaiful Md Yusof¹, Sabih Ul-Hassan¹, Zoe Wigston¹, Antonios Psarras², Jack Arnold¹, Lucy Carter³, Paul Emery⁴ and Ed Vital¹, ¹University of Leeds, Leeds, United Kingdom, ²Oxford University, Oxford, United Kingdom, ³University of Leeds, Hartlepool, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Many rheumatologists find it challenging to safely discharge "At-Risk" ANA-positive people at the first visit due to lack of cardinal signs and prediction tools.…
Abstract Number: 0565 • ACR Convergence 2023
Insulin Resistance and the Complement System Are Linked in Patients with Systemic Lupus Erythematosus
José María Viotti-Serra¹, Maria García-González¹, Fuensanta Gómez-Bernal¹, Juan Carlos Quevedo-Abeledo², Yolanda Fernández-Cladera¹, Agustín F González-Rivero¹, Miguel A Gonzalez-Gay³ and Ivan Ferraz Amaro¹, ¹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ²Hospital Doctor Negrín, Las Palmas de Gran Canaria, Spain, ³IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) patients more commonly have insulin resistance (IR) than control subjects. Recent studies have revealed that the complement (C) system is…
Abstract Number: 0583 • ACR Convergence 2023
Therapeutic Potential of Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, for the Treatment of Refractory Autoimmune Disease Patients
Racquel Domingo-Gonzalez¹, Isabelle Baribaud², Miho Oyasu¹, Sivani Pandey¹, Maya Leabman¹, Genevive Hernandez¹, Albert Candia¹, Stephen Carroll¹, Bruce Keyt¹, Maya Kotturi¹, Carrie Brodmerkel² and Mary Beth Harler², ¹IGM Biosciences, Inc., Mountain View, CA, ²IGM Biosciences, Inc., Doylestown, PA
Background/Purpose: B cell depletion therapy (BCDT) with conventional IgG antibodies (e.g.rituximab) has been used to treat autoimmune (AI) disease for several decades. However, many patients…
Abstract Number: 0600 • ACR Convergence 2023
Identification of Subsets of SLE Patients Responsive to Baricitinib by Transcriptomic Analysis at Baseline
Prathyusha Bachali¹, Amrie Grammer² and Peter Lipsky², ¹AMPEL BioSolutions, Redmond, WA, ²AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Baricitinib is an inhibitor of Jak1 approved for treatment of rheumatoid arthritis, atopic dermatitis, alopecia areata and Covid-19. A phase 2 trial showed success…
Abstract Number: 0785 • ACR Convergence 2023
Therapeutic Range of Hydroxychloroquine Blood Levels May Reduce Odds of High Lupus Disease Activity
Shivani Garg¹, Betty Chewning², Brad Astor³ and Christie M. Bartels³, ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Pharmacy, Madison, WI, ³University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) is the cornerstone of lupus (or SLE) treatment. Yet the optimal dosing of HCQ in SLE is unknown. Reducing HCQ dose to…
Abstract Number: 0893 • ACR Convergence 2023
Involvement of Type I Interferon-responsive Myeloid Cells in Renal Inflammation in a Lupus Mouse Model
Trine Jorgensen and Lindsey Han, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease that can cause damage to multiple organs, including the kidneys in Lupus Nephritis (LN). Current treatments…
Abstract Number: 0913 • ACR Convergence 2023
Neutrophils in Patients with Systemic Lupus Erythematosus Show Pronounced Inflammatory Signals
Annie Law¹, Chee Jian Pua², Dianyang Guo³, Chin Teck Ng⁴, Julian Thumboo¹, Andrea Hsiu Ling Low⁵ and Xiubo Fan¹, ¹Singapore General Hospital; Duke-NUS Medical School, Singapore, Singapore, ²National Heart Centre, Singapore, Singapore, ³Singapore General Hospital, Singapore, Singapore, ⁴Singapore General Hospital; Duke-NUS Medical School, Singapore, Malaysia, ⁵Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
Background/Purpose: IFN response, plasmablasts and neutrophils are three hallmarks of systemic lupus erythematosus (SLE). Studies showed that the netting neutrophils stimulated plasmacytoid dendritic cells to…
Abstract Number: 0933 • ACR Convergence 2023
The ‘Sweet’ in Lupus – IgG Glycosylation in Lupus Nephritis
Rhea Bhargava¹, Rohit Upadhyay², Scott Wenderfer³, Jing Chen² and George Tsokos⁴, ¹Tulane University, New Orleans, LA, ²Tulane University School of Medicine, New Orleans, LA, ³University of British Columbia, Vancouver, BC, Canada, ⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Lupus nephritis (LN) occurs in 50% of patients with systemic lupus erythematosus (SLE) for which we lack biomarkers, and an understanding of its pathogenesis.…
Abstract Number: 1230 • ACR Convergence 2023
Differences in Nailfold Capillary Morphology Distinguish Juvenile Dermatomyositis Patients That Are Myositis-Specific Autoantibody Positive
Nicholas McClellan, Sarah Vandenbergen, Sophia Matossian, J. Michelle Kahlenberg and Jessica Turnier, University of Michigan, Ann Arbor, MI
Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by multiorgan vasculopathy, and degree of vasculopathy can indicate more severe disease. Nailfold capillaroscopy is a non-invasive method to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].